[go: up one dir, main page]

CA2826387A1 - Procede d'inhibition de cellules tumorales d'hamartome - Google Patents

Procede d'inhibition de cellules tumorales d'hamartome Download PDF

Info

Publication number
CA2826387A1
CA2826387A1 CA2826387A CA2826387A CA2826387A1 CA 2826387 A1 CA2826387 A1 CA 2826387A1 CA 2826387 A CA2826387 A CA 2826387A CA 2826387 A CA2826387 A CA 2826387A CA 2826387 A1 CA2826387 A1 CA 2826387A1
Authority
CA
Canada
Prior art keywords
hydrogen
trifluoromethyl
compound
syndrome
hamartoma tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2826387A
Other languages
English (en)
Inventor
Jean J. ZHAO
Qi Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CA2826387A1 publication Critical patent/CA2826387A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2826387A 2011-02-11 2012-02-09 Procede d'inhibition de cellules tumorales d'hamartome Abandoned CA2826387A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161441896P 2011-02-11 2011-02-11
US61/441,896 2011-02-11
PCT/US2012/024440 WO2012109423A1 (fr) 2011-02-11 2012-02-09 Procédé d'inhibition de cellules tumorales d'hamartome

Publications (1)

Publication Number Publication Date
CA2826387A1 true CA2826387A1 (fr) 2012-08-16

Family

ID=45809596

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2826387A Abandoned CA2826387A1 (fr) 2011-02-11 2012-02-09 Procede d'inhibition de cellules tumorales d'hamartome

Country Status (11)

Country Link
US (1) US20140309221A1 (fr)
EP (1) EP2673268A1 (fr)
JP (1) JP2014505107A (fr)
KR (1) KR20140063509A (fr)
CN (1) CN103476765A (fr)
AU (1) AU2012214413A1 (fr)
BR (1) BR112013020159A2 (fr)
CA (1) CA2826387A1 (fr)
MX (1) MX2013009256A (fr)
RU (1) RU2013141559A (fr)
WO (1) WO2012109423A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
CN103012284A (zh) * 2012-12-26 2013-04-03 无锡捷化医药科技有限公司 一种2-氨基-5-溴嘧啶类化合物的制备方法
PE20151939A1 (es) 2013-03-14 2016-01-08 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
SG11201608658SA (en) * 2014-04-22 2016-11-29 Univ Basel Novel manufacturing process for triazine, pyrimidine and pyridine derivatives
CN105001151B (zh) * 2015-08-28 2017-07-14 苏州明锐医药科技有限公司 布帕尼西中间体及其制备方法
SG11201809652PA (en) * 2016-05-18 2018-12-28 Piqur Therapeutics Ag Treatment of skin lesions
US10993947B2 (en) 2016-05-18 2021-05-04 Torqur Treatment of skin lesions
CN106905294A (zh) * 2016-07-08 2017-06-30 苏州科睿思制药有限公司 5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺的晶型及其制备方法
CN106632443B (zh) * 2016-11-23 2022-06-17 山东友帮生化科技有限公司 一种2-氨基嘧啶-5-硼酸频哪酯硼酸盐的合成方法
WO2019101853A1 (fr) * 2017-11-23 2019-05-31 Piqur Therapeutics Ag Traitement de troubles cutanés
CN114213340B (zh) 2022-02-22 2022-06-07 北京蓝晶微生物科技有限公司 2,4-二氨基嘧啶氧化物的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
SG10201402867TA (en) * 2009-07-02 2014-08-28 Sanofi Sa Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors

Also Published As

Publication number Publication date
MX2013009256A (es) 2013-12-09
WO2012109423A1 (fr) 2012-08-16
CN103476765A (zh) 2013-12-25
RU2013141559A (ru) 2015-03-20
JP2014505107A (ja) 2014-02-27
AU2012214413A1 (en) 2013-08-22
KR20140063509A (ko) 2014-05-27
US20140309221A1 (en) 2014-10-16
EP2673268A1 (fr) 2013-12-18
BR112013020159A2 (pt) 2016-11-08

Similar Documents

Publication Publication Date Title
CA2826387A1 (fr) Procede d'inhibition de cellules tumorales d'hamartome
CA2938280C (fr) Composes de 4-amino-imidazoquinoline
EP3057962B1 (fr) Forme saline d'hydrochlorure pour inhibition d'ezh2
EP3040333B1 (fr) Formes crystallines de 5-(2,6-di-4-morpholinyl-4-pyridmidinyl)-4-trifluoromethylpyridin-2-amine, un inhibiteur de pik3
JP5008778B2 (ja) 新規５−フルオロウラシル誘導体
JP5498396B2 (ja) ヒスタミンｈ４受容体アンタゴニストとしての４−アミノピリミジン誘導体
TWI630203B (zh) 做為激酶抑制劑的喹唑啉類
WO2018191587A1 (fr) Inhibiteurs de kinases tam
CA3198096A1 (fr) Derives d'aryle pour le traitement de troubles a mediation par trpm3
CA2566213A1 (fr) 2-{[2-(2-methylamino-pyrimidine-4-yl)-1h-indole-5-carbonyle]-amine}-3-(phenylpyridine-2-yl-amine)-acide propionique substantiellement pur comme inhibiteur de kinase ikb
CN111655693A (zh) 抑制瞬时型感受器电位a1离子通道
EA014918B1 (ru) Замещенные бициклические пиримидоновые производные
CA2508319A1 (fr) Inhibiteur de jnk
KR20130025857A (ko) 2-［［［2-［(히드록시아세틸)아미노］-4-피리디닐］메틸］티오］-ｎ-［4-(트리플루오로메톡시)페닐］-3-피리딘카르복사미드의 벤젠술폰산염, 이의 결정, 이의 결정 다형 및 이들의 제조 방법
CN111377873B (zh) 氨基嘧啶化合物及其制备方法和用途
KR20160018686A (ko) 이환식 함질소 방향족 헤테로고리 아미드 화합물
EP3737683A1 (fr) Inhibiteurs de la protéine tyrosine phosphatase de faible poids moléculaire (lmptp) et utilisations associées
EP3057949B1 (fr) Modulateurs d'alcool secondaire de ror gamma t de type quinolinyle
WO2019001307A1 (fr) Composé amide, composition le contenant, et utilisation associée
JP2009073743A (ja) 新規な縮合環式ピリミジン化合物又はその塩、及びその医薬組成物
CN110612290A (zh) 新的苯并咪唑酮化合物和其医药用途
CN102746241A (zh) 2,3,5-三取代苯甲酰胺类化合物及其制备方法和用途
CN102512421A (zh) 哌嗪酰胺类化合物在制药中的新应用
HK40109783A (en) Hydrochloride salt form for ezh2 inhibition
CA2927152A1 (fr) Modulateurs quinolinyles a liaison phenyle de rar-gamma-t

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130801

FZDE Discontinued

Effective date: 20161013